Jean Boulle Luxury Group’s Proprietary Natural Gem Diamond Finish Technology Exhibited at Geneva Motor Show
The Jean Boulle Luxury Group (“the Group”) is pleased to announce that its patent-pending luxury diamond finish technology has been used in a paint exhibited on a Rolls-Royce Ghost at the 2017 Geneva Auto Show.
The Group worked with the Bespoke division of Rolls Royce Motor Cars Limited (“RRMC”) on the development of the finish for the luxury car displayed at the 2017 Geneva Motor Show. The result is a luxury automotive finish of unique and incomparable beauty.
The Group ethically sourced 1,000 natural gem-quality diamonds which were imported in full compliance with the Kimberley Process. The diamonds followed the Group’s proprietary process of selection, sorting, degreasing and acidization to guarantee the highest quality and brilliance before crushing the rough diamonds into millions of crystals of precise shape and size. They were also cleaned and then filtered for various specific characteristics before being delivered to RRMC.
Commenting on the launch, Pierre Bertrand Boulle, Jean Boulle Luxury CEO, said: “This is an exciting time for luxury car owners. The performance, beauty and ‘fire’ of the Jean Boulle Luxury Diamond finish has enthralled industry specialists and luxury designers. We look forward to expanding our unique proprietary product into other luxury market sectors.”
Building on the Group’s success in the luxury automotive market there are a range of applications for the diamond compound in other luxury sectors given the unique level of performance and aesthetics which this technology combines.
The Group intends to launch its aviation grade diamond coating application later this year for use on the exterior of private jets which will require over 30 million natural gem diamond crystals. Testing of the Group’s marine grade diamond coating for the superyacht sector is well advanced with projects underway in shipyards in the UK and Italy.
Jean Boulle Luxury Group
Michael Oke/Andy Mills
+44 (0)20 7321 0000
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum